Technology Enabled And Molecular Monitoring Of The Allograft And Transplant Recipient Study
1CareDx, South San Francisco, CA, 2University of Iowa, Iowa City, IA, 3University of Cincinnati, Cincinnati, OH
Meeting: 2022 American Transplant Congress
Abstract number: 9043
Keywords: Monitoring, Multicenter studies, Post-transplant hypertension, Rejection
Topic: Basic & Clinical Science » Basic & Clinical Science » 74 - Clinical Trials
Session Information
Session Time: 5:30pm-7:00pm
Presentation Time: 5:30pm-7:00pm
Location: Hynes Halls C & D
*Purpose: With the widespread availability of smart mobile devices, mobile health (mHealth) provides the opportunity to reach wide array of patients. Readmission rates as high as 45% have been reported amongst solid organ transplant (SOT) recipients and can be clinically and financially detrimental. Many readmissions can be prevented through utilization of novel technology to deliver post-transplant (PT) care in a patient centric manner. Pilot studies have demonstrated technology enabled patient monitoring leads to reduction in readmissions through early recognition and outpatient intervention. Here, we describe a large study utilizing AlloCare application for remote patient monitoring and its impact on SOT readmission rates.
*Methods: Technology Enabled And Molecular Monitoring of the Allograft and Transplant Recipient (TEAMMATE, NCT05033548) study is a prospective, multi-center, randomized, control study of 4,000 kidney, liver, heart, and lung transplant recipients. Patients will be randomized 1:1 in either AlloCare or standard of care arm. The primary objective of the study is all-cause reduction in readmission rates within 90 days PT. Secondary endpoints include biopsy-proven acute rejection, medication adherence, blood pressure and diabetes control within the first year and patient SF-36 scores at 90 days. Patients randomized to AlloCare arm will submit a summary statistics report of the health metrics monitored on a weekly basis for 90 days PT then monthly until 12 months PT.
*Results: Total of 6 sites have been activated thus far with the first patient enrolled in the study on November 16, 2021. There are currently 9 patients enrolled in the study. We anticipate nearly 100 sites to participate with the number of patients enrolled significantly increased in 2022.
*Conclusions: Role of mHealth has increased significantly in the last decade. With TEAMMATE being the largest prospective, multi-center, randomized, control study utilizing mHealth in SOT will demonstrate the impact of remote patient monitoring utilizing AlloCare on readmission rates.
To cite this abstract in AMA style:
Sulejmani N, Axelrod D, Dholakia S, Shah S. Technology Enabled And Molecular Monitoring Of The Allograft And Transplant Recipient Study [abstract]. Am J Transplant. 2022; 22 (suppl 3). https://atcmeetingabstracts.com/abstract/technology-enabled-and-molecular-monitoring-of-the-allograft-and-transplant-recipient-study/. Accessed May 30, 2025.« Back to 2022 American Transplant Congress